Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

beta-D-glucosylisophosphoramide mustard 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Metastatic Pancreatic Adenocarcinoma × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡